The Role of Colchicine in Atherosclerosis: From Bench to Bedside
Journal
Pharmaceutics
ISSN
1999-4923
Date Issued
2022
Author(s)
Leticia González
Juan Francisco Bulnes
María Paz Orellana
Gonzalo Martínez Rodriguez
Type
Resource Types::text::journal::journal article
URL Institutional Repository
Abstract
Inflammation is a key feature of atherosclerosis. The inflammatory process is involved in all stages of disease progression, from the early formation of plaque to its instability and disruption, leading to clinical events. This strongly suggests that the use of anti-inflammatory agents might improve both atherosclerosis progression and cardiovascular outcomes. Colchicine, an alkaloid derived from the flower Colchicum autumnale, has been used for years in the treatment of inflammatory pathologies, including Gout, Mediterranean Fever, and Pericarditis. Colchicine is known to act over microtubules, inducing depolymerization, and over the NLRP3 inflammasome, which might explain its known anti-inflammatory properties. Recent evidence has shown the therapeutic potential of colchicine in the management of atherosclerosis and its complications, with limited adverse effects. In this review, we summarize the current knowledge regarding colchicine mechanisms of action and pharmacokinetics, as well as the available evidence on the use of colchicine for the treatment of coronary artery disease, covering basic, translational, and clinical studies.
Cite this document
González, L., Bulnes, J. F., Orellana, M. P., Muñoz Venturelli, P., & Martínez Rodriguez, G. (2022). The role of colchicine in atherosclerosis: From bench to bedside. Pharmaceutics, 14(7), 1395. https://doi.org/10.3390/pharmaceutics14071395
Subjects
acute coronary syndrome
;
atherosclerosis
;
colchicine
;
coronary artery disease
;
inflammation
;
nlrp3 inflammasome
;
colchicine
;
cryopyrin
;
acute coronary syndrome
;
antiinflammatory activity
;
atherosclerosis
;
clinical research
;
coronary artery disease
;
disease model
;
drug mechanism
;
drug safety
;
gastrointestinal toxicity
;
human
;
inflammation
;
meta analysis (topic)
;
nonhuman
;
pathogenesis
;
phase 2 clinical trial (topic)
;
phase 3 clinical trial (topic)
;
preclinical study
;
review
;
translational research